These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2666667)

  • 1. Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol.
    Berger JG; Chang WK; Clader JW; Hou D; Chipkin RE; McPhail AT
    J Med Chem; 1989 Aug; 32(8):1913-21. PubMed ID: 2666667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepines.
    Weinstock J; Oh HJ; DeBrosse CW; Eggleston DS; Wise M; Flaim KE; Gessner GW; Sawyer JL; Kaiser C
    J Med Chem; 1987 Aug; 30(8):1303-8. PubMed ID: 2886663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
    Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
    J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral effects of D1 and D2 dopamine receptor antagonists in squirrel monkeys.
    Bergman J; Madras BK; Spealman RD
    J Pharmacol Exp Ther; 1991 Sep; 258(3):910-7. PubMed ID: 1890625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
    Makman MH; Dvorkin B
    Brain Res; 1986 Dec; 387(3):261-70. PubMed ID: 2950967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative activities of SCH 23390 and its analogs in three tests for D1/DA1 dopamine receptor antagonism.
    Barnett A; Ahn HS; Billard W; Gold EH; Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1986 Sep; 128(3):249-53. PubMed ID: 2878816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (+/-)-3-allyl-7-halo-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines as selective high affinity D1 dopamine receptor antagonists: synthesis and structure-activity relationship.
    Baindur N; Tran M; Niznik HB; Guan HC; Seeman P; Neumeyer JL
    J Med Chem; 1992 Jan; 35(1):67-72. PubMed ID: 1531075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
    Neumeyer JL; Kula NS; Baldessarini RJ; Baindur N
    J Med Chem; 1992 Apr; 35(8):1466-71. PubMed ID: 1533424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H]SCH 39166, a new D1-selective radioligand: in vitro and in vivo binding analyses.
    McQuade RD; Duffy RA; Anderson CC; Crosby G; Coffin VL; Chipkin RE; Barnett A
    J Neurochem; 1991 Dec; 57(6):2001-10. PubMed ID: 1834801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
    Pettersson I; Liljefors T; Bøgesø K
    J Med Chem; 1990 Aug; 33(8):2197-204. PubMed ID: 1973733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine.
    Snyder SE; Aviles-Garay FA; Chakraborti R; Nichols DE; Watts VJ; Mailman RB
    J Med Chem; 1995 Jun; 38(13):2395-409. PubMed ID: 7608904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship.
    Neumeyer JL; Baindur N; Niznik HB; Guan HC; Seeman P
    J Med Chem; 1991 Dec; 34(12):3366-71. PubMed ID: 1684995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.
    Charifson PS; Wyrick SD; Hoffman AJ; Simmons RM; Bowen JP; McDougald DL; Mailman RB
    J Med Chem; 1988 Oct; 31(10):1941-6. PubMed ID: 3050089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.
    O'Boyle KM; Waddington JL
    Eur J Pharmacol; 1984 Mar; 98(3-4):433-6. PubMed ID: 6144559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and resolution of (+-)-7-chloro-8-hydroxy-1-(3'-iodophenyl)-3-methyl-2,3,4,5-tetrahydro- 1H-3- benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor.
    Chumpradit S; Kung MP; Billings JJ; Kung HF
    J Med Chem; 1991 Mar; 34(3):877-83. PubMed ID: 1825848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of novel fluorescent ligands with high affinity for D1 and D2 dopaminergic receptors.
    Monsma FJ; Barton AC; Kang HC; Brassard DL; Haugland RP; Sibley DR
    J Neurochem; 1989 May; 52(5):1641-4. PubMed ID: 2523470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of radioiodinated TISCH: a high-affinity and selective ligand for mapping CNS D1 dopamine receptor.
    Billings JJ; Kung MP; Chumpradit S; Mozley D; Alavi A; Kung HF
    J Neurochem; 1992 Jan; 58(1):227-36. PubMed ID: 1530770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
    Charifson PS; Bowen JP; Wyrick SD; Hoffman AJ; Cory M; McPhail AT; Mailman RB
    J Med Chem; 1989 Sep; 32(9):2050-8. PubMed ID: 2527994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
    Minor DL; Wyrick SD; Charifson PS; Watts VJ; Nichols DE; Mailman RB
    J Med Chem; 1994 Dec; 37(25):4317-28. PubMed ID: 7996543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.